Pathology artificial intelligence (AI) software developer PathAI has raised $60 million in a series B funding round.
The Boston company said it plans to use the funding to improve its flagship pathology research platform, fund R&D for new tools and medical devices, and enhance its offerings to existing partners. PathAI has been signing partnerships with pharmaceutical companies to accelerate drug development, as well as with diagnostic laboratories to support pathologists in bringing faster and more accurate diagnostics to patients.
The funding round was led by equity firm General Atlantic, with participation from General Catalyst and existing investors. General Atlantic Managing Director Dr. Michelle Dipp, PhD, will join PathAI's board of directors as part of the investment.
